Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Combining Decitabine With Plerixafor Yields a High Response Rate In Newly Diagnosed Older Patients With AML

Gail J. Roboz, MD, Joseph M. Scandura, MD, PhD, Ellen Ritchie, MD, Yulia Dault, RN, Linda Lam, Wen Xie, Hsiao-Ting Hsu, Danielle Marshall, Paul J Christos, Cindy Ippoliti, Eric J. Feldman, MD, Monica L. Guzman, PhD

Blood (2013) 122 (21): 621.

https://doi.org/10.1182/blood.V122.21.621.621

Published: 2013

Journal Articles

A Novel Sequential Treatment Utilizing CPX-351 As Salvage Chemotherapy Followed by a Reduced Intensity Conditioning Allogeneic Stem-Cell Transplantation for Patients with Refractory Leukemia

Usama Gergis, MD, Gail J. Roboz, MD, Ellen Ritchie, MD, Joseph M. Scandura, MD, PhD, Karen-Sue B. Carlson, MD, PhD, Tsiporah B. Shore, MD, Sebastian Mayer, MD, Tomer M Mark, MD, MSc, Roger N Pearse, MD, PhD, June Greenberg, Tania J Curcio, R.N, Cindy Ippoliti, PharmD, Marshall McKenna, Eric J Feldman, MD

Blood (2011) 118 (21): 3030.

https://doi.org/10.1182/blood.V118.21.3030.3030

Published: 2011

Journal Articles

Epigenetic Priming with Decitabine Prior to Standard Induction Chemotherapy in Less-Than-Favorable Risk Acute Myelogenous Leukemia (AML).

Joseph M. Scandura, MD, PhD, Gail J. Roboz, MD, Michelle Moh, MS, Jahar R Bose, Usama S Gergis, MD, Sebastian A Mayer, MD, Cindy Ippoliti, PharmD, Curcio J Tania, RN, Ellen K Ritchie, MD, Eric J. Feldman, MD

Blood (2009) 114 (22): 3079.

https://doi.org/10.1182/blood.V114.22.3079.3079

Published: 2009

Journal Articles

Decitabine-Based Salvage Therapy in Adults with Acute Myeloid Leukemia.

Ellen K Ritchie, MD, Jon Arnason, MD, Eric J. Feldman, MD, Usama S Gergis, MD, Sebastian A Mayer, MD, Cindy Ippoliti, PharmD, Joseph M. Scandura, MD, PhD, Gail Roboz, MD

Blood (2009) 114 (22): 2063.

https://doi.org/10.1182/blood.V114.22.2063.2063

Published: 2009

Journal Articles

Campath-IH Combined with Fludarabine/Cyclophophamide/Rituximab (FCR) as Conditioning for Unrelated Non-Myeloablative Hematopoietic Transplantation (NMT) for Non-Hodgkin’s Lymphoma (NHL): Low Mortality Rate and Lower Than Expected Incidence of Cytomegalovirus (CMV) Reactivation.

Issa F. Khouri, MD, Jeffrey J. Tarrand, MD, Grace-Julia Okoroji, MS, Rima M. Saliba, PhD, Chitra M. Hosing, MD, Daniel R. Couriel, MD, Partow Kebriaei, MD, Donna Griffith, RN, Gabriela Rondon, MD, Cindy Ippoliti, PharmD, Richard E. Champlin, MD

Blood (2005) 106 (11): 2902.

https://doi.org/10.1182/blood.V106.11.2902.2902

Published: 2005

Journal Articles

Allogeneic Transplantation after an Alemtuzumab-Containing Myeloablative Conditioning Regimen for CD52 Positive Acute Lymphoblastic Leukemia (ALL).

Partow Kebriaei, MD, Rima M. Saliba, PhD, Carrie Ma, Cindy Ippoliti, PharmD, Daniel R. Couriel, MD, Marcos de Lima, MD, Sergio Giralt, MD, Muzaffar H. Qazilbash, MD, James L. Gajewski, MD, Chul S. Ha, MD, Richard E. Champlin, MD, Issa F. Khouri, MD

Blood (2005) 106 (11): 1135.

https://doi.org/10.1182/blood.V106.11.1135.1135

Published: 2005

Journal Articles

Clinical, Prognostic and Therapeutic Implications in the Diagnosis of Grade I Acute Graft-Versus-Host Disease.

Rima M. Saliba, PhD, Marcos de Lima, MD, Chitra Hosing, MD, Issa F. Khouri, MD, Sergio Giralt, MD, Paolo Anderlini, MD, Shubhra Ghosh, MD, Kerry Mickler, RN, Cindy Ippoliti, PHARMD, Zuraima Caldera, MD, Yvonne Hsu, PAC, Joyce Neumann, APN, Richard Champlin, MD, Daniel R. Couriel, MD

Blood (2005) 106 (11): 1799.

https://doi.org/10.1182/blood.V106.11.1799.1799

Published: 2005

Journal Articles

The Impact of Rituximab in the Development of Acute Graft Versus Host Disease (GVHD) Following Allogeneic Stem Cell Transplantation (SCT) for Acute Lymphoblastic Leukemia (ALL).

Partow Kebriaei, MD, Rima M. Saliba, PhD, Carrie Ma, Cindy Ippoliti, PharmD, Daniel R. Couriel, MD, Marcus de Lima, MD, Sergio Giralt, MD, Muzaffar H. Qazilbash, MD, James L. Gajewski, MD, Chul S. Ha, MD, Richard E. Champlin, MD, Issa F. Khouri, MD

Blood (2005) 106 (11): 1803.

https://doi.org/10.1182/blood.V106.11.1803.1803

Published: 2005

Journal Articles

Phase II/III Randomized Study Comparing Two Different Tacrolimus Blood Levels for the Prevention of Graft-Versus-Host Disease (GVHD).

Daniel R. Couriel, MD, Peter Thall, PhD, Kerry Mickler, RN, Marcos De Lima, MD, Sergio Giralt, MD, Muzaffar H. Qazilbash, MD, Chitra Hosing, MD, Issa Khouri, MD, Partow Kebriaei, MD, Yvonne Hsu, MD, Rima Saliba, MD, Cindy Ippoliti, PharmD, Richard Champlin, MD

Blood (2005) 106 (11): 142.

https://doi.org/10.1182/blood.V106.11.142.142

Published: 2005

Journal Articles

Allogeneic Transplantation for Adult Acute Lymphoblastic Leukemia (ALL) with Rituximab or Campath I-H.

Issa F. Khouri, MD, Rima M. Saliba, PhD, Partow Kebriaei, MD, Carrie Ma, Cindy Ippoliti, PharmD, Daniel R. Couriel, MD, Marcus de Lima, MD, Sergio Giralt, MD, Muzaffar H. Qazilbash, MD, James L. Gajewski, MD, Richard E. Champlin, MD

Blood (2004) 104 (11): 5132.

https://doi.org/10.1182/blood.V104.11.5132.5132

Published: 2004

Journal Articles

A Pilot Study for Haploidentical Transplant Using a Chemotherapy only Preparative Regimen eith T-Cell Depleted Haploidentical Transplant and Intensive Antibiotic Prophylaxis To Treat Advanced Leukemia Patients (pts).

James L. Gajewski, MD, Rima Saliba, PhD, John D. McMannis, PhD, Elizabeth J. Shpall, MD, Cindy Ippoliti, MD, Sergio A. Giralt, MD, Roy B. Jones, MD, Issa F. Khouri, MD, Chitra M. Hosing, MD, Martin J. Korbling, MD, Michele L. Donato, MD, Richard E. Champlin, MD

Blood (2004) 104 (11): 5184.

https://doi.org/10.1182/blood.V104.11.5184.5184

Published: 2004

Journal Articles

Allogeneic Stem Cell Transplantation with Reduced-Intensity, Fludarabine-Based Conditioning in Relapsed and Refractory Hodgkin’s Disease: Low Transplant-Related Mortality and Impact of Intensity of Conditioning Regimen on Survival.

Paolo Anderlini, MD, Rima Saliba, PhD, Michele Donato, MD, Sergio Giralt, MD, Borje Andersson, MD, Nato T. Ueno, MD, Issa F. Khouri, MD, Marcos de Lima, MD, Cindy Ippoliti, PharmD, Richard E. Champlin, MD

Blood (2004) 104 (11): 2135.

https://doi.org/10.1182/blood.V104.11.2135.2135

Published: 2004

Journal Articles

Tumor necrosis factor-α blockade for the treatment of acute GVHD

Daniel Couriel, Rima Saliba, Krystal Hicks, Cindy Ippoliti, Marcos de Lima, Chitra Hosing, Issa Khouri, Borje Andersson, James Gajewski, Michele Donato, Paolo Anderlini, Dimitrios P. Kontoyiannis, Agueda Cohen, Thomas Martin, Sergio Giralt, Richard Champlin

Blood (2004) 104 (3): 649–654.

https://doi.org/10.1182/blood-2003-12-4241

Published: 2004

Journal Articles

Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation

Marcos de Lima, Athanasios Anagnostopoulos, Mark Munsell, Munir Shahjahan, Naoto Ueno, Cindy Ippoliti, Borje S. Andersson, James Gajewski, Daniel Couriel, Jorge Cortes, Michele Donato, Joyce Neumann, Richard Champlin, Sergio Giralt

Blood (2004) 104 (3): 865–872.

https://doi.org/10.1182/blood-2003-11-3750

Published: 2004

Journal Articles

Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: donor type matters

Maha El-Zimaity, Rima Saliba, Kawah Chan, Munir Shahjahan, Antonio Carrasco, Ola Khorshid, Humberto Caldera, Daniel Couriel, Sergio Giralt, Issa Khouri, Cindy Ippoliti, Richard Champlin, Marcos de Lima

Blood (2004) 103 (12): 4674–4680.

https://doi.org/10.1182/blood-2003-08-2815

Published: 2004

Journal Articles

Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years

Raymond Wong, Sergio A. Giralt, Thomas Martin, Daniel R. Couriel, Athanasios Anagnostopoulos, Chitra Hosing, Borje S. Andersson, Pedro Cano, Munir Shahjahan, Cindy Ippoliti, Elihu H. Estey, John McMannis, James L. Gajewski, Richard E. Champlin, Marcos de Lima

Blood (2003) 102 (8): 3052–3059.

https://doi.org/10.1182/blood-2003-03-0855

Published: 2003

Journal Articles

Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality

Issa F. Khouri, Rima M. Saliba, Sergio A. Giralt, Ming-Sheng Lee, Grace-Julia Okoroji, Fredrick B. Hagemeister, Martin Korbling, Anas Younes, Cindy Ippoliti, James L. Gajewski, Peter McLaughlin, Paolo Anderlini, Michele L. Donato, Fernando F. Cabanillas, Richard E. Champlin

Blood (2001) 98 (13): 3595–3599.

https://doi.org/10.1182/blood.V98.13.3595

Published: 2001

NARROW

Combining Decitabine With Plerixafor Yields a High Response Rate In Newly Diagnosed Older Patients With AML

A Novel Sequential Treatment Utilizing CPX-351 As Salvage Chemotherapy Followed by a Reduced Intensity Conditioning Allogeneic Stem-Cell Transplantation for Patients with Refractory Leukemia

Epigenetic Priming with Decitabine Prior to Standard Induction Chemotherapy in Less-Than-Favorable Risk Acute Myelogenous Leukemia (AML).

Decitabine-Based Salvage Therapy in Adults with Acute Myeloid Leukemia.

Campath-IH Combined with Fludarabine/Cyclophophamide/Rituximab (FCR) as Conditioning for Unrelated Non-Myeloablative Hematopoietic Transplantation (NMT) for Non-Hodgkin’s Lymphoma (NHL): Low Mortality Rate and Lower Than Expected Incidence of Cytomegalovirus (CMV) Reactivation.

Allogeneic Transplantation after an Alemtuzumab-Containing Myeloablative Conditioning Regimen for CD52 Positive Acute Lymphoblastic Leukemia (ALL).

Clinical, Prognostic and Therapeutic Implications in the Diagnosis of Grade I Acute Graft-Versus-Host Disease.

The Impact of Rituximab in the Development of Acute Graft Versus Host Disease (GVHD) Following Allogeneic Stem Cell Transplantation (SCT) for Acute Lymphoblastic Leukemia (ALL).

Phase II/III Randomized Study Comparing Two Different Tacrolimus Blood Levels for the Prevention of Graft-Versus-Host Disease (GVHD).

Allogeneic Transplantation for Adult Acute Lymphoblastic Leukemia (ALL) with Rituximab or Campath I-H.

A Pilot Study for Haploidentical Transplant Using a Chemotherapy only Preparative Regimen eith T-Cell Depleted Haploidentical Transplant and Intensive Antibiotic Prophylaxis To Treat Advanced Leukemia Patients (pts).

Allogeneic Stem Cell Transplantation with Reduced-Intensity, Fludarabine-Based Conditioning in Relapsed and Refractory Hodgkin’s Disease: Low Transplant-Related Mortality and Impact of Intensity of Conditioning Regimen on Survival.

Tumor necrosis factor-α blockade for the treatment of acute GVHD

Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation

Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: donor type matters

Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years

Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only